Philips completes the acquisition of BioTelemetry, Inc.

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring. BioTelemetry’s financial results will be consolidated as part of Philips’ Connected Care business segment as of February 9, 2021.

The acquisition of BioTelemetry is a strong fit with Philips’ cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions. Philips’ patient care management solutions for the hospital include real-time patient monitoring, therapeutic devices, telehealth and informatics. Moreover, Philips has an advanced and secure cloud-based Philips HealthSuite digital platform optimized for the delivery of health care across care settings.

With 2020 sales of USD 450 million, BioTelemetry adds a complete range of clinically validated ambulatory cardiac diagnostics and monitoring services: Short-term Holter monitoring services, Long-term Holter monitoring services, Event recorder services, and Mobile Cardiac Outpatient Telemetry (MCOT) services. BioTelemetry has built one of the world's largest remote cardiac monitoring services networks, providing services for over one million patients per year. Additionally, BioTelemetry has a clinical research business that provides testing services for clinical trials.

"The combination of Philips' leading patient care management portfolio in the hospital with BioTelemetry's leading cardiac diagnostics and monitoring portfolio outside the hospital will result in a global leader in patient care management solutions for the hospital and the home for cardiac and other patients," said Frans van Houten, CEO of Royal Philips. "With our collective portfolios, and our healthcare informatics and services platforms, we will be in an optimal position to improve patient care across care settings for multiple diseases and medical conditions."

Financials

BioTelemetry and its approximately 1,900 employees will become part of Philips' Connected Care business segment. The acquisition is projected to be nominal sales growth and adjusted EBITA margin [1] accretive for Philips in 2021. Philips targets significant synergies driven by cross-selling opportunities, geographical expansion, and portfolio innovation synergies, such as Philips’ HealthSuite digital platform. Additionally, Philips will drive operational performance improvements through its proven productivity programs. The BioTelemetry business is expected to grow double-digits and to improve its Adjusted EBITA margin to more than 20% by 2025.

Transaction

The acquisition of BioTelemetry was structured as a merger under Section 251(h) of the General Corporation Law of the State of Delaware following the successful completion of Philips' previously announced tender offer to purchase all outstanding shares of common stock of BioTelemetry for USD 72.00 per share in cash, without interest, less any applicable withholding taxes. As a result of the merger, all remaining BioTelemetry shares were converted into the right to receive USD 72.00 per share in cash, without interest, less any applicable withholding taxes.

BioTelemetry has requested that NASDAQ files a Form 25 with the United States Securities and Exchange Commission causing the delisting of BioTelemetry’s common stock from NASDAQ. BioTelemetry’s common stock ceased trading prior to the opening of trading on February 9, 2021.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries.

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company provides remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.

1. Adjusted EBITA is defined as income from operations excluding amortization of acquired intangible assets, impairment of goodwill and other intangible assets, restructuring charges, acquisition-related costs and other significant items.

Most Popular Now

Alcidion Acquires UK Patient Flow Softwa…

Smart health technology provider Alcidion Group has today announced the strategic acquisition of ExtraMed, a UK company which specialises in providing NHS trusts with software that helps frontline staff make...

New AI Tool Tracks Evolution of COVID-19…

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time - a tool that could someday help public health officials combat...

Siemens Healthineers Completes Acquisiti…

Siemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020. "With Varian, Siemens...

Artificial Intelligence Model Predicts w…

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is...

Commission Opens First European Innovati…

Following the launch of the European Innovation Council (EIC) and the announcement of the first funding opportunities, today the Commission opened the first EIC Accelerator calls. The funding worth over...

Talking Health Tech

Opinion Article by Andy Kinnear, Partnerships Director, Ethical Healthcare Consulting. Ethical is different. The guy who founded it, [chief executive] Thomas Webb, comes from an NHS background and he is very...

International Master in Digital Health i…

The Master of Digital Health, MDH (formerly - Master of Medical Informatics, MMI) at European Campus Rottal-Inn (ECRI) - a branch of the Deggendorf University of Applied Sciences (DIT) in Bavaria...

Call for Papers: DigiHealthDay-2021

12 November 2021 The DigiHealthDay 2021 is an International Symposium with the theme "Global Digital Health - Today, Tomorrow, and Beyond". The abstracts pertaining to the field of digital health and...

Proposal for a Regulation Laying Down Ha…

Artificial Intelligence (AI) is a fast evolving family of technologies that can bring a wide array of economic and societal benefits across the entire spectrum of industries and social activities...

Leeds Hospitals go Live with Agfa Health…

Leeds Teaching Hospitals NHS Trust (LTHT) has successfully implemented Agfa HealthCare's Enterprise Imaging (EI) solution, a unified platform complete with clinical tools, reporting and a workflow engine that will help...

Digital Mental Health Interventions for …

An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed...

CoolClinical.com has Developed the First…

Cool Clinical announced the release of the publication on the first Artificial Intelligence system for predicting outcomes of cancer treatment, using data from clinical trials. This is a breakthrough for...